Bisphosphonate osteonecrosis of the jaw--a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention.
There has been an exponential rise in the literature of osteonecrosis and its complications in patients taking bisphosphonate drugs. Despite this increase, there is little evidence-based publications on how best to manage this complication. In this article (the first of two on bisphosphonate related jaw complications), we compare the guidelines produced by national specialist medical associations and expert panels on the prevention of bisphosphonate osteonecrosis of the jaws and review the evidence behind these guidelines.
Patel
Vinod
V
Oral & Maxillofacial Surgery, Guy's Hospital, London, UK.
McLeod
Niall M H
NM
Rogers
Simon N
SN
Brennan
Peter A
PA
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D017742:Dental Care for Chronically Ill; D004164:Diphosphonates / Q000009:adverse effects*; D055094:Evidence-Based Dentistry; D006291:Health Policy; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D006113:United Kingdom
D050071:Bone Density Conservation Agents; D004164:Diphosphonates